findmyKOL
Clinical trialNCT06239220RecruitingPhase 2Interventional

PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

SponsorGlenn J. HannaEnrollment25Head and Neck CancerHead and Neck Squamous Cell CarcinomaMetastatic Head and Neck CancerMetastatic Head-and-neck Squamous-cell CarcinomaRecurrent Head and Neck CancerRecurrent Head and Neck Squamous Cell Carcinoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Brigham and Women'S Hospital

    Boston, Massachusetts, United States

    Glenn J Hanna, MD
    Recruiting
  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

    Glenn J Hanna, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Feb 2024
Primary completion
31 Jul 2026
Completion
31 Jan 2027
Last update posted
11 Jun 2026
Registered enrollment
25
Registry id
NCT06239220

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.